Metastatic Castration-Sensitive Prostate Cancer: Evolving Management With New Data from ASCO 2025 - Episode 13
Final Thoughts: Importance of Treating mCSPC and Preserving Quality of Life
Panelists discuss how successful metastatic castration-sensitive prostate cancer (mCSPC) management requires balancing cancer control with quality-of-life preservation, emphasizing the need for better tools to measure patient-reported outcomes, comprehensive survivorship care addressing cardiovascular and bone health, and personalized approaches that help patients understand their prognosis while maintaining their ability to thrive during treatment.
Video content above is prompted by the following:
The evolution of mCSPC treatment emphasizes the critical importance of controlling cancer to preserve long-term quality of life, with many patients potentially thriving for years on effective therapy. Prognostic biomarkers, including clinical variables, disease volume, genomic markers, and prostate-specific antigen (PSA) response, provide valuable tools for personalized patient counseling about future expectations. This individualized prognostic information helps address patient anxieties about unknown outcomes while supporting informed treatment decisions. The field continues advancing with multiple treatment options entering the landscape, enabling patients to live longer while maintaining a better quality of life.
Optimal mCSPC care requires attention to the day-to-day lived experience of patients, not just laboratory values and imaging results. Clinicians must actively inquire about patient concerns during clinic visits, addressing symptoms and adverse effects that impact daily functioning. This approach recognizes that the time between major treatment decisions—while PSA decreases, scans remain stable, or disease begins progressing—constitutes most patient experience and significantly influences overall quality-of-life perception.
Future directions in mCSPC management must address several critical areas, including a better understanding of neurocognitive impacts, fatigue patterns, sleep disturbances, and neuropathy. The global shortage of quality health care providers amid an aging population and increasing cancer incidence necessitates efficient, systematic approaches to quality-of-life assessment. Important questions remain about treatment de-intensification strategies and optimal timing for reducing therapy burden while maintaining cancer control. Integration of nutrition and exercise programs alongside medical therapy represents another frontier for optimizing patient outcomes. The field’s continued evolution promises improved personalized care that maximizes survival and quality of life for patients facing metastatic prostate cancer.
Related Content:
